gvtcx

NHS National Pharmaceuticals Dasatinib and Paliperidone Injection

NHS England Published 27 Apr 2023 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£108,792,862
Statuscomplete
Category (CPV) 33600000
Deadline21 Feb 2023
Procedureopen
OCIDocds-h6vhtk-03981f

Awards (5)

This procurement was awarded to 5 suppliers. Values shown are per-award; the notice total is £108,792,862.

SupplierValueDateStatus
Janssen-Cilag Ltd shared · · active
Mercury Pharmaceuticals Limited shared · · active
Mylan shared · · active
Teva UK Limited shared · · active
Zentiva Pharma UK Ltd shared · · active

description

Proposed framework agreement for NHS National Generic Pharmaceuticals Dasatinib and Paliperidone Injection. Offer reference number: CM/PHG/22/5694<br/><br/><br/>Potential periods of call-offs under the framework agreement:<br/>CM/PHG/22/5694/00 - Dasatinib <br/>CESW 01/05/2023 – 30/04/2024 – (12 Months) <br/>LSNE 01/05/2023 – 30/04/2024 – (12 Months)<br/>NWLN 01/05/2023 – 30/04/2024 – (12 Months)<br/><br/>CM/PHG/22/5694/01 - Paliperidone Injection: <br/>LSNE 01/05/2023 – 31/05/2024 (13 Months) <br/>NWLN 01/05/2023 – 31/01/2025 (21 months)

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
17 Jan 2023 Contract notice (F02) Earlier regulations 001392-2023
27 Apr 2023 Contract award notice (F03) Earlier regulations 012161-2023

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.